Palisade Bio (PALI) R&D In Process (2021)
Palisade Bio (PALI) reported R&D In Process of $30.1 million for Q2 2021.
Palisade Bio (PALI) has 1 years of R&D In Process data on file, last reported at $30.1 million in Q2 2021.
- Quarterly R&D In Process changed N/A year-over-year to $30.1 million in Q2 2021, while the trailing twelve-month figure through Jun 2022 was $30.1 million (changed 0.0% YoY) and the FY2021 annual result came in at $30.1 million, changed N/A from the prior year.
- R&D In Process steadied at $30.1 million in Q2 2021 per PALI's latest filing.
- Across five years, R&D In Process topped out at $30.1 million in Q2 2021 and bottomed at $30.1 million in Q2 2021.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D In Process (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 500,000.00 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 101.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 30.12 Mn |